Literature DB >> 28421857

Risk of solid cancer in low dose-rate radiation epidemiological studies and the dose-rate effectiveness factor.

Roy Shore1, Linda Walsh2, Tamara Azizova3, Werner Rühm4.   

Abstract

PURPOSE: Estimated radiation risks used for radiation protection purposes have been based primarily on the Life Span Study (LSS) of atomic bomb survivors who received brief exposures at high dose rates, many with high doses. Information is needed regarding radiation risks from low dose-rate (LDR) exposures to low linear-energy-transfer (low-LET) radiation. We conducted a meta-analysis of LDR epidemiologic studies that provide dose-response estimates of total solid cancer risk in adulthood in comparison to corresponding LSS risks, in order to estimate a dose rate effectiveness factor (DREF).
MATERIALS AND METHODS: We identified 22 LDR studies with dose-response risk estimates for solid cancer after minimizing information overlap. For each study, a parallel risk estimate was derived from the LSS risk model using matching values for sex, mean ages at first exposure and attained age, targeted cancer types, and accounting for type of dosimetric assessment. For each LDR study, a ratio of the excess relative risk per Gy (ERR Gy-1) to the matching LSS ERR risk estimate (LDR/LSS) was calculated, and a meta-analysis of the risk ratios was conducted. The reciprocal of the resultant risk ratio provided an estimate of the DREF.
RESULTS: The meta-analysis showed a LDR/LSS risk ratio of 0.36 (95% confidence interval [CI] 0.14, 0.57) for the 19 studies of solid cancer mortality and 0.33 (95% CI 0.13, 0.54) when three cohorts with only incidence data also were added, implying a DREF with values around 3, but statistically compatible with 2. However, the analyses were highly dominated by the Mayak worker study. When the Mayak study was excluded the LDR/LSS risk ratios increased: 1.12 (95% CI 0.40, 1.84) for mortality and 0.54 (95% CI 0.09, 0.99) for mortality + incidence, implying a lower DREF in the range of 1-2. Meta-analyses that included only cohorts in which the mean dose was <100 mGy yielded a risk ratio of 1.06 (95% CI 0.30, 1.83) for solid cancer mortality and 0.58 (95% CI 0.10, 1.06) for mortality + incidence data.
CONCLUSIONS: The interpretation of a best estimate for a value of the DREF depends on the appropriateness of including the Mayak study. This study indicates a range of uncertainty in the value of DREF between 1 and about 2 after protracted radiation exposure. The LDR data provide direct evidence regarding risk from exposures at low dose rates as an important complement to the LSS risk estimates used for radiation protection purposes.

Entities:  

Keywords:  Low dose-rate; dose rate effectiveness factor; epidemiologic studies; meta-analysis; occupational radiation exposure

Mesh:

Year:  2017        PMID: 28421857     DOI: 10.1080/09553002.2017.1319090

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  18 in total

1.  High CT doses return to the agenda.

Authors:  W Rühm; R M Harrison
Journal:  Radiat Environ Biophys       Date:  2019-12-16       Impact factor: 1.925

Review 2.  Dose limits for occupational exposure to ionising radiation and genotoxic carcinogens: a German perspective.

Authors:  Werner Rühm; Joachim Breckow; Günter Dietze; Anna Friedl; Rüdiger Greinert; Peter Jacob; Stephan Kistinger; Rolf Michel; Wolfgang-Ulrich Müller; Heinz Otten; Christian Streffer; Wolfgang Weiss
Journal:  Radiat Environ Biophys       Date:  2019-11-01       Impact factor: 1.925

3.  Dose and dose rate extrapolation factors for malignant and non-malignant health endpoints after exposure to gamma and neutron radiation.

Authors:  Van Tran; Mark P Little
Journal:  Radiat Environ Biophys       Date:  2017-09-22       Impact factor: 1.925

4.  Radiation cancer risk at different dose rates: new dose-rate effectiveness factors derived from revised A-bomb radiation dosimetry data and non-tumor doses.

Authors:  Hiroshi Tanooka
Journal:  J Radiat Res       Date:  2022-01-20       Impact factor: 2.724

5.  Radio-biologically motivated modeling of radiation risks of mortality from ischemic heart diseases in the Canadian fluoroscopy cohort study.

Authors:  Helmut Schöllnberger; Jan Christian Kaiser; Markus Eidemüller; Lydia B Zablotska
Journal:  Radiat Environ Biophys       Date:  2019-11-28       Impact factor: 1.925

6.  Probability Distribution of Dose and Dose-Rate Effectiveness Factor for use in Estimating Risks of Solid Cancers From Exposure to Low-Let Radiation.

Authors:  David C Kocher; A Iulian Apostoaei; F Owen Hoffman; John R Trabalka
Journal:  Health Phys       Date:  2018-06       Impact factor: 1.316

7.  A bespoke health risk assessment methodology for the radiation protection of astronauts.

Authors:  Linda Walsh; Luana Hafner; Ulrich Straube; Alexander Ulanowski; Anna Fogtman; Marco Durante; Guillaume Weerts; Uwe Schneider
Journal:  Radiat Environ Biophys       Date:  2021-04-30       Impact factor: 1.925

Review 8.  Typical doses and dose rates in studies pertinent to radiation risk inference at low doses and low dose rates.

Authors:  Werner Rühm; Tamara Azizova; Simon Bouffler; Harry M Cullings; Bernd Grosche; Mark P Little; Roy S Shore; Linda Walsh; Gayle E Woloschak
Journal:  J Radiat Res       Date:  2018-04-01       Impact factor: 2.724

9.  Risk bases can complement dose bases for implementing and optimising a radiological protection strategy in urgent and transition emergency phases.

Authors:  Linda Walsh; Alexander Ulanowski; Jan Christian Kaiser; Clemens Woda; Wolfgang Raskob
Journal:  Radiat Environ Biophys       Date:  2019-07-25       Impact factor: 1.925

Review 10.  Multidisciplinary European Low Dose Initiative (MELODI): strategic research agenda for low dose radiation risk research.

Authors:  M Kreuzer; A Auvinen; E Cardis; M Durante; M Harms-Ringdahl; J R Jourdain; B G Madas; A Ottolenghi; S Pazzaglia; K M Prise; R Quintens; L Sabatier; S Bouffler
Journal:  Radiat Environ Biophys       Date:  2017-12-15       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.